Barclays Raises Illumina's Price Target to $85, Maintains 'Underweight' Rating
Jun 25, 2025 16:50
CST Updated
16:50
Illumina
Diagnostic Product Developer
Gelonghui June 25 | Barclays raised Illumina's target price from $77 to $85 and maintained an "Underweight" rating. (Gelonghui)